AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status
出版年份 2018 全文链接
标题
AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status
作者
关键词
-
出版物
BRITISH JOURNAL OF CANCER
Volume 118, Issue 11, Pages 1453-1463
出版商
Springer Nature
发表日期
2018-05-10
DOI
10.1038/s41416-018-0086-x
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Inhibition of the CSF-1 receptor sensitizes ovarian cancer cells to cisplatin
- (2018) Rong Yu et al. CELL BIOCHEMISTRY AND FUNCTION
- Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406).
- (2017) Scott Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling
- (2016) Zoi Karoulia et al. CANCER CELL
- BRAF-Directed Therapy in Metastatic Colorectal Cancer
- (2016) Krittiya Korphaisarn et al. CANCER JOURNAL
- Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
- (2015) Maria Romina Girotti et al. CANCER CELL
- Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
- (2015) Filippo Pietrantonio et al. EUROPEAN JOURNAL OF CANCER
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
- (2015) David M. Hyman et al. NEW ENGLAND JOURNAL OF MEDICINE
- BRAF in metastatic colorectal cancer: the future starts now
- (2015) Armando Orlandi et al. PHARMACOGENOMICS
- Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations
- (2015) L. G. Ahronian et al. Cancer Discovery
- Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma
- (2014) A. M. Menzies et al. CLINICAL CANCER RESEARCH
- BRAF Inhibitor Therapy for Melanoma, Thyroid and Colorectal Cancers: Development of Resistance and Future Prospects
- (2014) Md Rahman et al. CURRENT CANCER DRUG TARGETS
- BRAF inhibitor–associated ERK activation drives development of chronic lymphocytic leukemia
- (2014) Niuscha Yaktapour et al. JOURNAL OF CLINICAL INVESTIGATION
- A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors
- (2014) D. J. Konieczkowski et al. Cancer Discovery
- Emerging insights into resistance to BRAF inhibitors in melanoma
- (2013) Amanda D. Bucheit et al. BIOCHEMICAL PHARMACOLOGY
- Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3
- (2013) Ethan V. Abel et al. JOURNAL OF CLINICAL INVESTIGATION
- Discovery and Optimization of a Novel Series of Potent Mutant B-RafV600E Selective Kinase Inhibitors
- (2013) Melissa M. Vasbinder et al. JOURNAL OF MEDICINAL CHEMISTRY
- Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF -Mutant Thyroid Carcinomas
- (2013) Cristina Montero-Conde et al. Cancer Discovery
- Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents
- (2012) M. Mao et al. CLINICAL CANCER RESEARCH
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
- (2012) Timothy R. Wilson et al. NATURE
- Vemurafenib: the first drug approved for BRAF-mutant cancer
- (2012) Gideon Bollag et al. NATURE REVIEWS DRUG DISCOVERY
- EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
- (2012) Ryan B. Corcoran et al. Cancer Discovery
- Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
- (2012) Maria R. Girotti et al. Cancer Discovery
- Phosphorylation of CSF-1R Y721 mediates its association with PI3K to regulate macrophage motility and enhancement of tumor cell invasion
- (2011) N. G. Sampaio et al. JOURNAL OF CELL SCIENCE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
- (2010) Jessie Villanueva et al. CANCER CELL
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Profiling Y561-Dependent and -Independent Substrates of CSF-1R in Epithelial Cells
- (2010) Melodie L. Knowlton et al. PLoS One
- Immunodeficient Mouse Strains Display Marked Variability in Growth of Human Melanoma Lung Metastases
- (2009) B. M. Carreno et al. CLINICAL CANCER RESEARCH
- Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
- (2008) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL ONCOLOGY
- BRAF Silencing by Short Hairpin RNA or Chemical Blockade by PLX4032 Leads to Different Responses in Melanoma and Thyroid Carcinoma Cells
- (2008) E. Sala et al. MOLECULAR CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More